Benzodiazepines of Long and Short Elimination Half-life and the Risk of Hip Fracture

Wayne A. Ray

JAMA · 1989 · 539 citations · 14 references

Concepts

TL;DR

The study aimed to assess whether hip‑fracture risk differs between users of benzodiazepines with long versus short elimination half‑lives among adults aged 65+ in Saskatchewan. A nested case‑control design identified 4,501 hip‑fracture cases and 24,041 controls from 1977‑1985 records, with current benzodiazepine exposure defined by a prescription filled within the prior 30 days. Current use of long half‑life benzodiazepines was associated with a 1.7‑fold higher hip‑fracture risk (95% CI 1.5–2.0) compared with a 1.1‑fold risk (95% CI 0.9–1.3) for short half‑life drugs, and this association remained unchanged after adjusting for demographic, clinical, and functional factors. JAMA 1989;262:3303‑3307.

Abstract

To determine if the risk of hip fracture differed between persons receiving benzodiazepines with long (≥24 hours) or short (&lt;24 hours) elimination half-lives, we conducted a nested case-control study among residents of the Canadian province of Saskatchewan who were 65 years of age and older. We identified 4501 cases occurring between 1977 and 1985 from computerized hospital records and 24 041 population controls. Current benzodiazepine use, defined as having filled a prescription in the past 30 days, was ascertained from computerized pharmacy records. The relative risk of hip fracture was 1.7 (95% confidence interval, 1.5 to 2.0) for current users of long half-life benzodiazepines, in contrast to that of 1.1 (95% confidence interval, 0.9 to 1.3) for current users of short half-life drugs. This finding was not altered by sex, age, calendar year, nursing home residence, or history of hospitalization. Medical record review for a sample of 189 cases suggested that this finding was not due to confounding by dementia, ambulatory status, functional status, or body mass. (<i>JAMA</i>. 1989;262:3303-3307)

References

14